[Therapeutic guidelines on ulcerative colitis: a GRADE methodology based effort of GETECCU].

[1]  B. Feagan,et al.  Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. , 2016, The Cochrane database of systematic reviews.

[2]  A. Griffiths,et al.  Methotrexate for maintenance of remission in ulcerative colitis. , 2015, The Cochrane database of systematic reviews.

[3]  Daniel Gilbert,et al.  Stumbling on Happiness , 2015 .

[4]  S. Kedia,et al.  Management of acute severe ulcerative colitis. , 2014, World journal of gastrointestinal pathophysiology.

[5]  E. Cabré,et al.  Decision tree for early introduction of rescue therapy in active ulcerative colitis treated with steroids , 2011, Inflammatory bowel diseases.

[6]  C. O'Morain,et al.  Review article: defining remission in ulcerative colitis , 2011, Alimentary pharmacology & therapeutics.

[7]  Tariq Ahmad,et al.  Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47 , 2011, Nature Genetics.

[8]  S. Schreiber,et al.  The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organization: When to Start, When to Stop, Which Drug to Choose, and How to Predict Response? , 2011, The American Journal of Gastroenterology.

[9]  S. Schreiber,et al.  Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial , 2011, Gut.

[10]  M. Sans,et al.  Usefulness of oral beclometasone dipropionate in the treatment of active ulcerative colitis in clinical practice: the RECLICU Study. , 2010, Journal of Crohn's & colitis.

[11]  L. Mackillop,et al.  European evidenced-based consensus on reproduction in inflammatory bowel disease. , 2010, Journal of Crohn's & colitis.

[12]  P. Hellström,et al.  Clinical trial: colectomy after rescue therapy in ulcerative colitis – 3‐year follow‐up of the Swedish‐Danish controlled infliximab study , 2010, Alimentary pharmacology & therapeutics.

[13]  H. Tajiri,et al.  What's Hot in the Red Journal This Month? , 2010, The American Journal of Gastroenterology.

[14]  A. Gasbarrini,et al.  Treatment of Relapsing Mild-to-Moderate Ulcerative Colitis With the Probiotic VSL#3 as Adjunctive to a Standard Pharmaceutical Treatment: A Double-Blind, Randomized, Placebo-Controlled Study , 2010, The American Journal of Gastroenterology.

[15]  R. Horne,et al.  Factors Associated With Non-Adherence to Oral Medication for Inflammatory Bowel Disease: A Systematic Review , 2010, The American Journal of Gastroenterology.

[16]  H. J. de Silva,et al.  The Asia‐Pacific consensus on ulcerative colitis , 2010, Journal of gastroenterology and hepatology.

[17]  M. Safdi,et al.  5-ASA Dose-Response: Maximizing Efficacy and Adherence. , 2010, Gastroenterology & hepatology.

[18]  J. Reguła,et al.  Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis. , 2009, Gastroenterology.

[19]  S. Hanauer,et al.  Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. , 2009, Gastroenterology.

[20]  M. Silverberg,et al.  A systematic prospective comparison of noninvasive disease activity indices in ulcerative colitis. , 2009, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[21]  A. Griffiths,et al.  Appraisal of the pediatric ulcerative colitis activity index (PUCAI) , 2009, Inflammatory bowel diseases.

[22]  G. Porro,et al.  Maintenance Treatment With Azathioprine in Ulcerative Colitis: Outcome and Predictive Factors After Drug Withdrawal , 2009, The American Journal of Gastroenterology.

[23]  D. Jewell,et al.  Long‐term outcome after admission for acute severe ulcerative colitis in Oxford: The 1992–1993 cohort , 2009, Inflammatory bowel diseases.

[24]  H. Masnou,et al.  Infliximab Rescue Therapy after Cyclosporin Failure in Steroid-Refractory Ulcerative Colitis , 2009, Digestion.

[25]  E. Vittinghoff,et al.  Hospitalized ulcerative colitis patients have an elevated risk of thromboembolic events. , 2009, World journal of gastroenterology.

[26]  J. Mate,et al.  P119 - Efficacy of azathioprine and mercaptopurine in ulcerative colitis. Systematic review and meta-analysis , 2009 .

[27]  I. Gorelov,et al.  Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial , 2008, Gut.

[28]  R. Vega,et al.  Cytomegalovirus infection in ulcerative colitis: A prospective, comparative study on prevalence and diagnostic strategy , 2008, Inflammatory bowel diseases.

[29]  F. Gomollón.  Enfermedad inflamatoria intestinal , 2008 .

[30]  Justina J. Sam,et al.  Rising Prevalence of Venous Thromboembolism and Its Impact on Mortality Among Hospitalized Inflammatory Bowel Disease Patients , 2008, The American Journal of Gastroenterology.

[31]  T. Hibi,et al.  Randomized , Double-Blind , Sham-Controlled Study of ranulocyte / Monocyte Apheresis for Active Ulcerative Colitis , 2008 .

[32]  B. Feagan,et al.  Tacrolimus (FK506) for induction of remission in refractory ulcerative colitis. , 2008, The Cochrane database of systematic reviews.

[33]  W. Bemelman,et al.  European Evidence-based Consensus on the Management of Ulcerative Colitis: Current Management , 2007 .

[34]  A. Forbes,et al.  European evidence-based Consensus on the management of ulcerative colitis: Special situations. , 2008, Journal of Crohn's & colitis.

[35]  B F Warren,et al.  European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Definitions and diagnosis. , 2008, Journal of Crohn's & colitis.

[36]  W. Cacheux,et al.  Predictive Factors of Response to Cyclosporine in Steroid-Refractory Ulcerative Colitis , 2008, The American Journal of Gastroenterology.

[37]  S. Schreiber,et al.  Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis , 2008, Gut.

[38]  M. Lean,et al.  Malnutrition in hospitals , 2008, BMJ : British Medical Journal.

[39]  A. Berstad,et al.  Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases. , 2007, Inflammatory bowel diseases.

[40]  R. Dickinson,et al.  Clinical trial: oral prednisolone metasulfobenzoate (Predocol) vs. oral prednisolone for active ulcerative colitis , 2007, Alimentary pharmacology & therapeutics.

[41]  R. Cohen,et al.  Review article: increasing the dose of oral mesalazine therapy for active ulcerative colitis does not improve remission rates , 2007, Alimentary pharmacology & therapeutics.

[42]  M. M. Castillejo,et al.  El sistema GRADE para la toma de decisiones clínicas y la elaboración de recomendaciones y guías de práctica clínica , 2007 .

[43]  F. Manguso,et al.  Meta‐analysis: the efficacy of rectal beclomethasone dipropionate vs. 5‐aminosalicylic acid in mild to moderate distal ulcerative colitis , 2007, Alimentary pharmacology & therapeutics.

[44]  A. Mazzoni,et al.  Treatment of patients with acute ulcerative colitis: conventional corticosteroid therapy (MP) versus granulocytapheresis (GMA): a pilot study. , 2007, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[45]  S. Nikfar,et al.  A Meta-Analysis of Antibiotic Therapy for Active Ulcerative Colitis , 2007, Digestive Diseases and Sciences.

[46]  A. Sapino,et al.  Colectomy rate in steroid-refractory colitis initially responsive to cyclosporin: a long-term retrospective cohort study , 2007, BMC gastroenterology.

[47]  Philippe Marteau,et al.  A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. , 2007, Gastroenterology.

[48]  J. Mate,et al.  Systematic review: infliximab therapy in ulcerative colitis , 2006, Alimentary pharmacology & therapeutics.

[49]  A. Moss,et al.  Infliximab for induction and maintenance therapy for ulcerative colitis. , 2006, Gastroenterology.

[50]  H. Steinhart,et al.  Medical management of left‐sided ulcerative colitis and ulcerative proctitis: Critical evaluation of therapeutic trials , 2006, Inflammatory bowel diseases.

[51]  J. Mate,et al.  The Role of Tacrolimus in Inflammatory Bowel Disease: A Systematic Review , 2006, Digestive Diseases and Sciences.

[52]  C. O'Morain,et al.  Cost analysis and cost determinants in a European inflammatory bowel disease inception cohort with 10 years of follow-up evaluation. , 2006, Gastroenterology.

[53]  A. Akobeng,et al.  Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis. , 2006, The Cochrane database of systematic reviews.

[54]  P. Rutgeerts,et al.  Incidence of colectomy during long-term follow-up after cyclosporine-induced remission of severe ulcerative colitis. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[55]  J. Satsangi,et al.  The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications , 2006, Gut.

[56]  B. Wiedenmann,et al.  Tacrolimus Is Safe and Effective in Patients with Severe Steroid-Refractory or Steroid-Dependent Inflammatory Bowel Disease—A Long-Term Follow-Up , 2006, The American Journal of Gastroenterology.

[57]  J. Cabriada,et al.  Documento de consenso en el uso de la granulocitoaféresis en pacientes con enfermedad inflamatoria intestinal , 2006 .

[58]  C. O'Morain,et al.  Disease outcome of inflammatory bowel disease patients: General outline of a Europe-wide population-based 10-year clinical follow-up study , 2006, Scandinavian journal of gastroenterology. Supplement.

[59]  S. García-López,et al.  Cyclosporine in the treatment of severe attack of ulcerative colitis: a systematic review. , 2005, Gastroenterologia y hepatologia.

[60]  J. Satsangi,et al.  Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. , 2005, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[61]  G. Porro,et al.  A rare cause of diuretic refractory ascites , 2005, Gut.

[62]  P. Marteau,et al.  An unusual cause of soft tissue infection , 2005, Gut.

[63]  Å. Danielsson,et al.  Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. , 2005, Gastroenterology.

[64]  A. Francavilla,et al.  A New Oral Delivery System for 5‐ASA: Preliminary Clinical Findings for MMX , 2005, Inflammatory bowel diseases.

[65]  E. Doménech,et al.  Recomendaciones GETECCU-2005 para el uso de infliximab (Remicade®) en la enfermedad inflamatoria intestinal , 2005 .

[66]  K. Soares-Weiser,et al.  Cyclosporine A for induction of remission in severe ulcerative colitis. , 2005, The Cochrane database of systematic reviews.

[67]  D. Jewell,et al.  Ciclosporin use in acute ulcerative colitis: a long-term experience , 2005, European journal of gastroenterology & hepatology.

[68]  H. Herfarth,et al.  Controlled, open, randomized multicenter trial comparing the effects of treatment on quality of life, safety and efficacy of budesonide foam and betamethasone enemas in patients with active distal ulcerative colitis. , 2004, Hepato-gastroenterology.

[69]  A. Gasbarrini,et al.  Infliximab in the treatment of steroid-dependent ulcerative colitis. , 2004, European review for medical and pharmacological sciences.

[70]  S. Travis,et al.  Guidelines for the management of inflammatory bowel disease in adults , 2004, Gut.

[71]  Tatsuo Tanaka,et al.  Adsorptive Granulocyte and Monocyte Apheresis versus Prednisolone in Patients with Corticosteroid-Dependent Moderately Severe Ulcerative Colitis , 2004, Digestion.

[72]  P. Rutgeerts,et al.  Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. , 2003, Gastroenterology.

[73]  S. Campbell,et al.  Combination immunomodulatory therapy with cyclosporine and azathioprine in corticosteroid-resistant severe ulcerative colitis: the Edinburgh experience of outcome. , 2003, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[74]  A. Forbes,et al.  Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial , 2003, Gut.

[75]  G. Porro,et al.  Budesonide Foam vs. Hydrocortisone Acetate Foam in the Treatment of Active Ulcerative Proctosigmoiditis , 2003, Diseases of the colon and rectum.

[76]  F. Manguso,et al.  Oral beclometasone dipropionate in the treatment of extensive and left‐sided active ulcerative colitis: a multicentre randomised study , 2003, Alimentary pharmacology & therapeutics.

[77]  E. Cabré,et al.  Azathioprine without oral ciclosporin in the long‐term maintenance of remission induced by intravenous ciclosporin in severe, steroid‐refractory ulcerative colitis , 2002, Alimentary pharmacology & therapeutics.

[78]  F. Manguso,et al.  Oral beclometasone dipropionate in the treatment of active ulcerative colitis: a double‐blind placebo‐controlled study , 2002, Alimentary pharmacology & therapeutics.

[79]  D. Jewell,et al.  The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review , 2002, Gut.

[80]  R. Sadik,et al.  Longer term outcome of steroid refractory ulcerative colitis treated with intravenous cyclosporine without subsequent oral cyclosporine maintenance therapy , 2002, International Journal of Colorectal Disease.

[81]  F. Manguso,et al.  Oral beclomethasone dipropionate in patients with mild to moderate ulcerative colitis: A dose-finding study , 2001, Advances in therapy.

[82]  E. Cabré,et al.  Nutrition in inflammatory bowel disease: impact on disease and therapy. , 2001, Current opinion in gastroenterology.

[83]  L. Mortelmans,et al.  Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. , 2001, Gastroenterology.

[84]  P. Usai,et al.  Oral versus combination mesalazine therapy in active ulcerative colitis: a double‐blind, double‐dummy, randomized multicentre study , 2001, Alimentary pharmacology & therapeutics.

[85]  R. Moreno-otero,et al.  6‐Mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid‐dependent inflammatory bowel disease , 2000, European journal of gastroenterology & hepatology.

[86]  S. Hanauer,et al.  Comparative Tolerability of Treatments for Inflammatory Bowel Disease , 2000, Drug safety.

[87]  M. Sans,et al.  Comparison of heparin and steroids in the treatment of moderate and severe ulcerative colitis. , 2000, Gastroenterology.

[88]  Margus,et al.  Efficacy and tolerability of mesalazine foam enema (Salofalk foam) for distal ulcerative colitis: a double‐blind, randomized, placebo‐controlled study , 2000, Alimentary pharmacology & therapeutics.

[89]  J. Marshall,et al.  Putting rectal 5-aminosalicylic acid in its place: the role in distal ulcerative colitis , 2000, American Journal of Gastroenterology.

[90]  L. Good,et al.  Long-term use of mesalamine (Rowasa) suppositories in remission maintenance of ulcerative proctitis , 2000, American Journal of Gastroenterology.

[91]  R. Thisted,et al.  A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis , 2000, American Journal of Gastroenterology.

[92]  S. Hanauer,et al.  Intravenous cyclosporin in ulcerative colitis: a five-year experience , 1999, American Journal of Gastroenterology.

[93]  S. Hanauer,et al.  Budesonide enema for the treatment of active, distal ulcerative colitis and proctitis: a dose-ranging study. U.S. Budesonide enema study group. , 1998, Gastroenterology.

[94]  R. Pounder,et al.  A simple clinical colitis activity index , 1998, Gut.

[95]  S. Hanauer.  Dose‐Ranging Study of Mesalamine (PENTASA) Enemas in the Treatment of Acute Ulcerative Proctosigmoiditis: Results of a Multicentered Placebo‐Controlled Trial , 1998 .

[96]  G. Porro,et al.  Maintenance treatment of ulcerative proctitis with mesalazine suppositories: a double-blind placebo-controlled trial , 1998, American Journal of Gastroenterology.

[97]  Orlando,et al.  Beclomethasone dipropionate enemas versus prednisolone sodium phosphate enemas in the treatment of distal ulcerative colitis , 1998, Alimentary pharmacology & therapeutics.

[98]  P. Gionchetti,et al.  Comparison of oral with rectal mesalazine in the treatment of ulcerative proctitis , 1998, Diseases of the colon and rectum.

[99]  S. Targan,et al.  A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. , 1997, The American journal of gastroenterology.

[100]  S. Hanauer,et al.  Cyclosporin for severe ulcerative colitis: a user's guide. , 1997, The American journal of gastroenterology.

[101]  J. Marshall,et al.  Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis. , 1997, Gut.

[102]  P. Fockens,et al.  Beclomethasone dipropionate (3 mg) versus 5-aminosalicylic acid (2 g) versus the combination of both (3 mg/2 g) as retention enemas in active ulcerative proctitis. , 1996, European journal of gastroenterology & hepatology.

[103]  Å. Danielsson,et al.  Oral budesonide versus prednisolone in patients with active extensive and left-sided ulcerative colitis. , 1996, Gastroenterology.

[104]  S. Hanauer,et al.  Cyclosporine in severe ulcerative colitis refractory to steroid therapy. , 1994, The New England journal of medicine.

[105]  S. Targan,et al.  Inflammatory Bowel Disease: From Bench to Bedside , 1994 .

[106]  E. Cabré,et al.  Enteral versus parenteral nutrition as adjunct therapy in acute ulcerative colitis. , 1993, The American journal of gastroenterology.

[107]  T. Yao,et al.  An index of disease activity in patients with ulcerative colitis. , 1992, The American journal of gastroenterology.

[108]  N. Greenberger,et al.  5-Aminosalicylic acid enemas: effective agent in maintaining remission in left-sided ulcerative colitis. , 1988, Gastroenterology.

[109]  W. Tremaine,et al.  Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. , 1987, The New England journal of medicine.

[110]  G. Järnerot,et al.  Intensive intravenous treatment of ulcerative colitis. , 1985, Gastroenterology.

[111]  A. Montserrat,et al.  [Level of food consumption and its possible role in the development of protein-calorie malnutrition in hospitalized gastroenterology patients]. , 1985, Medicina clinica.

[112]  S. Truelove,et al.  Optimum dose of sulphasalazine for maintenance treatment in ulcerative colitis. , 1980, Gut.

[113]  S. Truelove,et al.  FURTHER EXPERIENCE IN THE TREATMENT OF SEVERE ATTACKS OF ULCERATIVE COLITIS , 1978, The Lancet.

[114]  J. H. Baron,et al.  A double blind controlled trial of prednisolone-21-phosphate suppositories in the treatment of idiopathic proctitis , 1962, Gut.

[115]  G. Watkinson,et al.  Treatment of Ulcerative Colitis with Topical Hydrocortisone Hemisuccinate Sodium , 1958, British medical journal.

[116]  S. Truelove,et al.  Cortisone in Ulcerative Colitis , 1954 .

[117]  S. Truelove.  Cortisone in ulcerative colitis; preliminary report on a therapeutic trial. , 1954, Gastroenterologia.

[118]  J. Macdonald,et al.  Methotrexate for induction of remission in ulcerative colitis. , 2014, The Cochrane database of systematic reviews.

[119]  M. Picco.  A Multicenter Experience With Infliximab for Ulcerative Colitis: Outcomes and Predictors of Response, Optimization, Colectomy, and Hospitalization , 2011 .

[120]  Malfertheiner,et al.  World Gastroenterology Organization Practice Guidelines for the diagnosis and management of IBD in 2010. , 2010, Inflammatory bowel diseases.

[121]  H. Tilg,et al.  European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. , 2009, Journal of Crohn's & colitis.

[122]  G. Lichtenstein.  Continuous Infusion Versus Bolus Administration of Steroids in Severe Attacks of Ulcerative Colitis: A Randomized, Double-Blind Trial , 2008 .

[123]  G. Lichtenstein.  Development, Validation, and Evaluation of a Pediatric Ulcerative Colitis Activity Index: A Prospective Multicenter Study , 2008 .

[124]  M. Kamm,et al.  Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. , 2007, Gastroenterology.

[125]  M. Kamm,et al.  Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[126]  A. Griffiths,et al.  Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[127]  A. Timmer,et al.  Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. , 2007, The Cochrane database of systematic reviews.

[128]  M. Vieth,et al.  The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamine. , 2003, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[129]  S. Hanauer,et al.  Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. , 2003, The American journal of medicine.

[130]  J. Macdonald,et al.  Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. , 2003, The Cochrane database of systematic reviews.

[131]  J. Gisbert,et al.  Preguntas y respuestas sobre el papel de la azatioprina y la 6-mercaptopurina en el tratamiento de la enfermedad inflamatoria intestinal , 2002 .

[132]  J. Mate,et al.  Role of 5-aminosalicylic acid (5-ASA) in treatment of inflammatory bowel disease: a systematic review. , 2002, Digestive diseases and sciences.

[133]  Å. Danielsson,et al.  A steroid enema, budesonide, lacking systemic effects for the treatment of distal ulcerative colitis or proctitis. , 1992, Scandinavian journal of gastroenterology.

[134]  J. Lennard-jones,et al.  Classification of inflammatory bowel disease. , 1989, Scandinavian journal of gastroenterology. Supplement.